Matrix-Bio's goal is to be a leading provider of metabolite-based testing in the fast-growing molecular diagnostic testing market.

Matrix-Bio, Inc., is an Indiana-based life science company focused on the development and commercialization of advanced metabolite profiling-based blood tests for early cancer detection, recurrence detection, and chemotherapy monitoring that offer greater accuracy than current testing methodologies. The company's initial focus is breast cancer; however, its patent-pending platform for identifying small molecule biomarkers shows great potential for other cancers and diseases due to its sensitivity and specificity in detecting characteristic changes in the body's metabolism.

The company's first product is MetaMarker-BCR, an exceptionally accurate, reliable test for monitoring patients for the recurrence of breast cancer, an important concern for breast cancer survivors. The first test of its kind in the world, MetaMarker-BCR has significant market potential. Currently, there are 2.5 million women in the United States who have had breast cancer. Following the completion of their cancer treatment, women remain in the care of a medical oncologist for approximately three years for the express purpose of identifying a recurrence of cancer.

Because MetaMarker-BCR relies on a simple blood draw and not a tissue sample, the test is simple for medical practices to implement yet it is a powerful tool for detecting recurring cancer. MetaMarker-BCR will be followed by a powerful test for breast cancer screening.

Matrix-Bio is a privately held company, and has no securities registered with the Securities and Exchange Commission or under any applicable state laws regulating the offer and sale of securities. The content of this web page does not constitute an offer to sell any securities or any other interest in Matrix-Bio. Offers to sell any securities or other interests in the Company are made only to sophisticated and "accredited investors" (as such term is defined in Rule 501 adopted under the Securities Act of 1933, the "1933 Act") who have a pre-existing relationship with the Company or that meet other specifically required relationship requirements. An offer to sell securities will only be made to such persons and such an offer can only be made by delivery from the Company of a private offering memorandum or other documents sufficient to meet the informational requirements for perfecting a private placement under Regulation D adopted under the 1933 Act and analogous and applicable state laws. There is no market for the Company's securities, none is expected to develop for the foreseeable future and no broker or other person not involved in the management of the Company has any authority to offer or sell any securities of the Company.